Corticosteroids have been used in the management of autoimmune blistering diseases
(AIBD) for more than 50 years, and are an essential component in the pharmacologic …

Autoimmune blistering diseases (AIBD) often require high-dose corticosteroids and
immunosuppressive agents for adequate control. These diseases cause significant …

This review highlights some of the recent advances and controversies in the treatment of
autoimmune blistering diseases, with an emphasis on the practical management of these …

Autoimmune blistering diseases are rare, but potentially debilitating cutaneous disorders
characterized by varying degrees of mucosal and cutaneous bullae formation. Topical …

Autoimmune skin diseases represent a heterogeneous group of disorders with grossly
diverging clinical manifestations but partly shared underlying immunological mechanisms …

The treatment of autoimmune blistering diseases has improved over the past 5 years owing
to advances in our ability to monitor, predict, and prevent side effects associated with the …

This article reviews recent advances in the treatment and management of bullous diseases
with glucocorticoids. Since the 1950s, when oral cortisone acetate was introduced for the …

Autoimmune bullous diseases are a heterogeneous group of disorders that can be
subdivided according to the level of split formation in the intraepidermal blistering …

Autoimmune mucocutaneous blistering diseases (AMBD) are an interesting group of rare
diseases that affect the mucous membranes and the skin and are frequently or potentially …

Detlef Zillikens, MD, director and chair of the Department of Dermatology at the University of
Lübeck, Lübeck, Germany, died in September 2022, aged only 64. He dedicated his …